Overview of upcoming calls

Ramune Midttveit
April 25

**FRIPRO**: bottom-up «frontier research», high gain – high risk

**BEHANDLING**

**BEDREHELSE**: bottom-up, user orientated, anticipated benefit

**HELSEVEL**

**INTAPRT**: research and education through long term international cooperation
The highest priority is developing and strengthening intervention research.

Are you investigating the effect of a measure designed to prevent persons who have a risk factor from developing a disease?

Are you investigating the causes of why healthy persons develop a disease (biological, genetic, environmental, health habits, etc.)?

Are you investigating the effect of measures to prevent people from being exposed to things with known health impacts (drop-out from school, bullying, noise, pollution, etc.)?

Are you investigating what promotes good quality of life in people and which factors are associated with quality of life?

Are the project’s objects of study healthy persons who do not have an established diagnosis/are not patients?

Are the project’s objects of study healthy persons who have one or more risk factors (health habits, biological or genetic risk, etc.), but who have not yet become ill/been given a diagnosis?
BEHANDLING

BEHANDLING is targeted towards research on patients, i.e. the entire disease trajectory (including diagnostics, treatment and rehabilitation) of persons already suffering from a diagnosed disease, injury, or the like.

Are you investigating the efficacy of a treatment and a clinical endpoint where efficacy is primarily measured as change in patients’ survival rates, disease, symptoms, quality of life, or the like?

Are you following the trajectory of a disease or developments over time for a group of patients?

Are you investigating the efficacy of a procedure, surgical operation, pharmacological treatment, functional training, rehabilitation, etc. for patients?

Are you investigating the efficacy of an intervention to prevent patients with a diagnosis (who have been recruited to the study because they have that diagnosis) from experiencing deterioration in their disease or developing other diseases?

Are you investigating how a treatment intervention affects patients’ quality of life?
The main focus is placed on factors that have an impact on the services: organisation, quality, efficiency, competency, finances, innovation, and the like.

Is the project’s object(s) of study an organisation or a service?

Are you investigating the impact of the organisation of a treatment? Is the endpoint to be measured as efficiency, costs, utilisation of resources, participation in working life, etc.? 
Useful links:

PROSJEKTBANKEN

https://www.forskningsradet.no/prosjektbanken/#/explore/projects/Kilde=FORISS&chart=bar&calcType=funding&Sprak=no

SØKNADER TIL FORSKNINGSRÅDATET

https://public.tableau.com/profile/forskningsr.det#!/vizhome/SknadertilForskningsrdet-enkeltsknader/Enkeltsknader
Bakgrunnen for satsningen er å stimulere til økt internasjonalt forskningssamarbeid med USA, som har store og dyktige forskningsmiljøer innenfor forebyggende- og helsefremmende arbeid, årsaksforskning og klinisk behandlingsforskning. The background for the initiative is to stimulate increased international research collaboration with the United States, which has large and skilled research environments in preventive and health promotion, cause research and clinical treatment research.

Det kan søkes om 5 – 7 millioner kroner til å dekke den norske delen av et samarbeidsprosjekt. NIH er positive til ordningen, og vil annonseret det til de amerikanske forskningsmiljøene. Forskningsrådet har tidligere hatt en pilotutlysning innenfor psykisk helse, rusmiddelforskning og nevroforskning.

It may be requested of NOK 5 - 7 million to cover the Norwegian part of a cooperation project. NIH is positive to the scheme and will announce it to the American research communities. The Research Council has previously had a pilot announcement in mental health, drug research and neuroprojection.

Deadline: September 12
Pre-announcement: Nordic Call on Personalised Medicine

- Data: Knowledge and value generation, based on use of cross-Nordic omics and health care data, for PM purposes, leading to new PM hypotheses to e.g. be tested in the clinic, and for supporting development of best data practices (access, quality and harmonisation) across the Nordic countries.
- Clinical/regulatory: Development and implementation of solutions to overcome clinical and regulatory challenges related to PM.
- Health economics: Research and development of health economics models that are useful in a PM setting.

The expected funding available per project is in the order of EUR 1-3 million for a duration of up to 4 years

Deadline: September 4
Other calls

**INFRUSTRUKTUR** (May 15)

**ExstraStiftelsen** (April 16)

**Kreftforeningen** (June 1)

**HelseVest** (September 15)

**EU** (various)

Please read more about external funding opportunities [here](#).